Parcourir par sujet "beta 3 adrenergic receptor"
Voici les éléments 1-7 de 7
-
Best practice in the management of storage symptoms in male lower urinary tract symptoms: a review of the evidence base
(2018)Storage lower urinary tract symptoms (LUTS) are characterized by an altered bladder sensation, increased daytime frequency, nocturia, urgency and urgency incontinence. Some evidence underlines the role of metabolic factors, ... -
Denominator changes may obscure results from single-well assays: β3-adrenoceptor ligand-induced changes of cell number as example
(2017)[No abstract available] -
Desensitization of cAMP accumulation via human β3-adrenoceptors expressed in human embryonic kidney cells by full, partial, and biased agonists
(2019)β3-Adrenoceptors couple not only to cAMP formation but, at least in some cell types, also to alternative signaling pathways such as phosphorylation of extracellular signal-regulated kinase (ERK). β3-Adrenoceptor agonists ... -
Do β3-adrenoceptor agonists cause urinary bladder smooth muscle relaxation by inhibiting acetylcholine release?
(2017)[No abstract available] -
A low-protein, high-carbohydrate diet increases browning in perirenal adipose tissue but not in inguinal adipose tissue
(2017)Objective The aim of this study was to evaluate the browning and origin of fatty acids (FAs) in the maintenance of triacylglycerol (TG) storage and/or as fuel for thermogenesis in perirenal adipose tissue (periWAT) and ... -
A low-protein, high-carbohydrate diet stimulates thermogenesis in the brown adipose tissue of rats via ATF-2
(2016)The aim of this study was to evaluate thermogenesis in the interscapular brown adipose tissue (IBAT) of rats submitted to low-protein, high-carbohydrate (LPHC) diet and the involvement of adrenergic stimulation in this ... -
Safety and tolerability of β 3-adrenoceptor agonists in the treatment of overactive bladder syndrome - Insight from transcriptosome and experimental studies
(2016)Introduction: We have reviewed the safety and tolerability of β3-adrenoceptor agonists, specifically mirabegron and solabegron, a newly emerging drug class for the treatment of the overactive bladder syndrome. We discuss ...